Literature DB >> 6274647

Influence of naloxone and methysergide on the analgesic effect of clomipramine in rats.

A Eschalier, J L Montastruc, J L Devoize, F Rigal, G Gaillard-Plaza, J C Pechadre.   

Abstract

The effects of the tricyclic antidepressant clomipramine were studied in two analgesic tests in rats: (1) vocalization threshold response; and (2) scored behavioral response to electric shock to the tail. Clomipramine (20-50 mg/kg i.p.) produced analgesia, decreasing behavioral response scores and increasing vocalization threshold. Morphine also reduced the response scores in the second test. Naloxone (0.8 mg/kg i.p) or methysergide (20 mg/kg i.p.) (no effect when given alone) abolished the analgesic effect of clomipramine as evaluated by vocalization threshold response. Naloxone alone (0.6 or 2 mg/kg i.p.) increased the behavioral response at 20 and 30 V but did not modify the score at 40 V. Naloxone reduced the analgesic effect of clomipramine or morphine in the behavioral test. These results suggest that the analgesic effect of clomipramine could involve both serotonergic and endorphin central systems.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6274647     DOI: 10.1016/0014-2999(81)90316-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Antidepressants as analgesics: an overview of central and peripheral mechanisms of action.

Authors:  J Sawynok; M J Esser; A R Reid
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

2.  Chronic antidepressant counteracts the conditioned analgesia induced by a context previously associated with inescapable shock.

Authors:  V S Murua; V A Molina
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems.

Authors:  Liting Deng; Wan-Hung Lee; Zhili Xu; Alexandros Makriyannis; Andrea G Hohmann
Journal:  Pharmacol Res       Date:  2016-10-20       Impact factor: 7.658

4.  Chronic administration of clomipramine prevents the increase in serotonin and noradrenaline induced by chronic stress.

Authors:  A Adell; C García-Marquez; A Armario; E Gelpí
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Potentiation of the antinociceptive effect of clomipramine by a 5-ht(1A) antagonist in neuropathic pain in rats.

Authors:  D Ardid; A Alloui; G Brousse; D Jourdan; P Picard; C Dubray; A Eschalier
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

6.  κ-Opioid receptors are not necessary for the antidepressant treatment of neuropathic pain.

Authors:  Salim Megat; Yohann Bohren; Stephane Doridot; Claire Gaveriaux-Ruff; Brigitte L Kieffer; Marie-José Freund-Mercier; Ipek Yalcin; Michel Barrot
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

7.  Influence of naloxone on antidepressant drug effects in the forced swimming test in mice.

Authors:  J L Devoize; F Rigal; A Eschalier; J F Trolese; M Renoux
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  A comparison of the effects of vitamin B12 and aspirin in three experimental pain models in rats and mice.

Authors:  A Eschalier; O Aumaître; A Decamps; G Dordain
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Noradrenergic and opioidergic influences on the antinociceptive effect of clomipramine in the formalin test in rats.

Authors:  M Ansuategui; L Naharro; M Feria
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  Thiamine, riboflavin, and nicotinamide inhibit paclitaxel-induced allodynia by reducing TNF-α and CXCL-1 in dorsal root ganglia and thalamus and activating ATP-sensitive potassium channels.

Authors:  Alysson V Braga; Sarah O A M Costa; Felipe F Rodrigues; Ivo S F Melo; Marcela I Morais; Márcio M Coelho; Renes R Machado
Journal:  Inflammopharmacology       Date:  2019-08-06       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.